Skip to content
While some US federal regulators believe the ongoing intensification of mergers and acquisitions in various sectors could jeopardize market competition, M&As can be beneficial […]
M&As in biotech can help patients, says AskBio Read More »
“Another pandemic is upon us, and policymakers are once again proving slow to respond, to the detriment of global health,” writes Henry B. Skinner,
AMR: ‘We’re already ignoring the next pandemic’ Read More »
On Day 4 – the final episode of Good Day BIO Live – we have interviews with BIO leadership and policy experts on Accelerated
Good Day BIO LIVE! from San Diego – watch Thursday’s episode Read More »
Accelerated Approval, growing misinformation and declining life expectancy, and the need for more resources on the food side of the agency were among the
FDA Commissioner on Accelerated Approval, misinformation, and food Read More »
The Senate Health, Education, Labor and Pensions (HELP) Committee marked up its legislation to reauthorize the Food and Drug Administration (FDA) user fee agreements,
FDA user fee bill marked up by Senate HELP Committee Read More »
The draft of the next Food and Drug Administration (FDA) user fee agreement currently making its way through Congress was developed with close cooperation
PDUFA panelists praise FDA’s cooperation on setting drug approval process Read More »
On Day 3, the Good Day BIO Team brings you exclusive interviews with BIO’s Phyllis Arthur, Novavax’s John Trizzino, and BioGENEius winner Okezue Bell,
Good Day BIO LIVE! from San Diego – watch Wednesday’s episode Read More »
The Food and Drug Administration’s greater reliance on digital tools during the pandemic showed the agency how these tools could be used to expand
FDA officials see benefits of pandemic-driven digitalization Read More »
The COVID-19 pandemic shook up the global health care system in ways that were more unique and acute than in years past. Yet, the
How do you get an entire population vaccinated and boosted? Read More »
The U.S. Federal Trade Commission (FTC) announced last week that it will investigate the “prescription drug middleman industry,” demanding information and records regarding the
FTC will investigate six largest pharmacy benefit managers Read More »
